Bristol-Myers Squibb jumps after Q1 revenue and EPS beat, outlook reaffirmed
BMY•Bristol-Myers Squibb shares are higher after the company reported Q1 2026 results that beat expectations on revenue and adjusted EPS. The company posted about $11.5B in revenue (+3% YoY) and reaffirmed full-year 2026 guidance, pointing to continued momentum in its Growth Portfolio (+12% to $6.2B).
1. What’s moving the stock
Bristol-Myers Squibb is rising today after reporting first-quarter 2026 earnings that came in ahead of Wall Street expectations, alongside commentary that the company is “off to a good start” for the year and a reaffirmation of full-year 2026 guidance. The earnings print is being read as a sign that newer products are increasingly offsetting pressure from older, more exposed franchises. (stocktitan.net)
2. The numbers investors are reacting to
Bristol-Myers reported roughly $11.5 billion in Q1 2026 total revenue (about +3% year over year reported, +1% excluding FX). The company’s Growth Portfolio increased 12% to $6.2 billion, while the Legacy Portfolio declined 6%, reflecting expected generic erosion; adjusted (non-GAAP) EPS was reported at $1.58 in several recaps of the release and call. (stocktitan.net)
3. Guidance and the key debate behind today’s pop
The positive price action is largely tied to the combination of an earnings beat and management keeping its 2026 outlook intact, which investors are treating as a confidence signal despite ongoing patent-expiration and mix pressures. The market focus remains on whether accelerating growth brands can continue to backfill declines in the legacy base as the year progresses. (tipranks.com)
